The Potential Therapeutic Role of Hydroxyethyl Starch and Hydrocortisone in Acute Aluminum Phosphide Poisoning

NACompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

July 15, 2020

Primary Completion Date

February 28, 2024

Study Completion Date

March 30, 2024

Conditions
Potential Therapeutic Role
Interventions
DRUG

Hydroxyethyl Starch 130-0.4 60 MG/ML [Voluven]

Hydroxyethyl starch dose is 500 cc in 6 hours

DRUG

Hydrocortisone

Hydrocortisone dose is 200-300 mg /day intravenously

DRUG

Placebo

received the standard ALP treatment according to TUPTC protocol as follows: patient resuscitation, care of airway, breathing and circulation, gastric decontamination with 2 ampoules sodium bicarbonate (each ampoule 25 ml containing 2.1 gm sodium bicarbonate) followed by activated charcoal in dose of 1 g/Kg orally, adequate hydration, normal saline administration (0.9% Sodium Chloride IV), vasopressors IV infusions, inhalation of 100% oxygen, ranitidine IV, magnesium sulfate IV infusion and other supportive treatment.

Trial Locations (1)

31527

Tarek Abdel Hay, Tanta

All Listed Sponsors
lead

Tanta University

OTHER

NCT04465539 - The Potential Therapeutic Role of Hydroxyethyl Starch and Hydrocortisone in Acute Aluminum Phosphide Poisoning | Biotech Hunter | Biotech Hunter